Black Press BlackPressUSA Business Commentary Community Featured Government Health Lead Story National News Newswire Politics science
Black Press BlackPressUSA Commentary Community Entertainment Featured Lifestyle Music National News Newswire Press Releases Religion
Black Press BlackPressUSA Business Community Education Featured HBCU Lead Story National News Newswire Sports
Black Press BlackPressUSA Business Community Education Featured HBCU Lead Story National News Newswire
Art Black History Black Press BlackPressUSA Business Community Education Entertainment Featured Music National News Newswire
AFRO-AMERICAN – WASHINGTON — A recent announcement regarding a new treatment for metastatic pancreatic cancer, daraxonrasib, has shown it doubled survival rates for patients and reduced the risk of death by 60 percent. This breakthrough stemmed from sustained, peer-reviewed scientific investment.
Published
on
By
For more than three decades, my work has been rooted in West Baltimore, where the gap between scientific progress and community benefit is not theoretical; it is something families experience every day.
That is why a recent announcement about a new treatment for metastatic pancreatic cancer demanded my attention. New clinical data shows that daraxonrasib doubled survival rates for patients with previously treated metastatic pancreatic cancer, reducing the risk of death by 60 percent. For a disease that has long resisted treatment, this is not incremental progress—it is a turning point.
This breakthrough did not happen by accident. It is the direct result of sustained, peer-reviewed scientific investment — exactly the kind of research championed by institutions like Johns Hopkins, which has served as an anchor of innovation and healing for generations in our city.
Maryland, with its extraordinary concentration of public and private research assets, has a particular stake in protecting that legacy.
That is why I am alarmed by a proposed federal rule that would give political appointees veto power over health research grants. Maryland Congressman Jamie Raskin has warned that this change would stifle healthcare innovation for generations. He is right. The peer-review system that produced daraxonrasib works precisely because science — not politics — guides the decisions.
“The peer-review system that produced daraxonrasib works precisely because science — not politics — guides the decisions.”
“The peer-review system that produced daraxonrasib works precisely because science — not politics — guides the decisions.”
Undermining that system, whether through politicized grant oversight or pricing policies like most-favored-nation pricing and IRA expansion, puts the next breakthrough at risk before it ever reaches a patient — including those in communities that have historically been the last to benefit and the first to lose.
The opinions expressed in this commentary are those of the writer and not necessarily those of the AFRO.
The post Science, not politics, must guide lifesaving medical research appeared first on AFRO American Newspapers.
Based on reporting by Afro-American – Washington.
Fed Court to Decide Landmark First Amendment Case
Vibes Texas Brings Black Independent Artists to National Stage for Wingstop House of Flavor
Young Candidate Hopes to Make History in South Carolina’s 4th Congressional District
PRESS ROOM: Martha’s Vineyard Gospel Festival Returns with Wintley Phipps and National Gospel Artists for an Evening Where Music Meets Community Impact
TSU Names Jennifer Bell Interim Director of Athletics
How Howard University Is Fixing a 500 Student Enrollment Scare
Apollo HTX: Showcases the City’s Undiscovered Talent
Trump Shell Game Biggest Grift in World History
Copyright © 2026 National Newspaper Publishers Association. All rights reserved.